Lyell Immunopharma to Participate in BofA Securities Healthcare Conference
May 02 2023 - 4:05PM
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell
reprogramming company advancing a diverse pipeline of cell
therapies for patients with solid tumors, today announced that
members of its senior management team will participate in the
BofA Securities 2023 Healthcare Conference on Tuesday,
May 9 at 3:00 pm PT.
A live webcast of the fireside chat can be
accessed through the investor relations section of the Company's
website at www.lyell.com. Following the live presentation, a replay
of the webcast will be available on the Company's website for 90
days following the presentation date.
About Lyell Immunopharma,
Inc.
Lyell is a clinical-stage T-cell reprogramming
company advancing a diverse pipeline of cell therapies for patients
with solid tumors. The technologies powering its product candidates
are designed to address barriers that limit consistent and
long-lasting responses to cell therapy for solid tumors: T-cell
exhaustion and lack of durable stemness, which includes the ability
to persist and self-renew to drive durable tumor cytotoxicity.
Lyell is applying its proprietary ex vivo genetic and epigenetic
reprogramming technologies to address these barriers in order to
develop new medicines with improved durable clinical outcomes.
Lyell is based in South San Francisco, California with facilities
in Seattle and Bothell, Washington. To learn more, please visit
www.lyell.com.
Contact:Ellen RoseSenior Vice
President, Communications and Investor Relationserose@lyell.com
Lyell Immunopharma (NASDAQ:LYEL)
Historical Stock Chart
From Apr 2024 to May 2024
Lyell Immunopharma (NASDAQ:LYEL)
Historical Stock Chart
From May 2023 to May 2024